GO
Loading...

Pfizer Inc

More

  • Most active New York Stock Exchange-traded stocks Monday, 17 Nov 2014 | 2:22 PM ET

    NEW YORK— A look at New York Stock Exchange 10 most-active stocks at the close of trading:. Baker Hughes Inc. rose 8.9 percent to $65.23 with 52,847,300 shares traded. Bank of America Corp. fell. 3 percent to $17.09 with 41,213,800 shares traded.

  • Midday Glance: Pharmaceuticals companies Monday, 17 Nov 2014 | 2:21 PM ET

    Baxter International Inc. rose$. 16 or. 2 percent, to $71.91. Bristol-Myers Squibb Co. rose$. 30 or. 5 percent, to $58.25. Hospira rose$. 23 or. 4 percent, to $58.51.

  • US, German drugmakers team up on cancer medicines Monday, 17 Nov 2014 | 1:47 PM ET

    Under their agreement, New York- based Pfizer will pay Merck KGaA $850 million initially and up to $2 billion total, based on how many drugs are approved and future revenue levels. Pfizer said it will take a charge for the $850 million payment, cutting into profit this year, so it's lowered its 2014 earnings forecast by a dime, to a range of $1.40 to $1.49 per share.

  • CHICAGO, Nov 17- After years of uncertainty, a nearly decade-long study showed that Merck& Co's cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients when used with an effective statin. Christopher Cannon, lead investigator of the 18,144- patient Improve-It study presented at the American Heart Association...

  • CHICAGO, Nov 17- Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck& Co's Zetia, according to data from a clinical trial presented on Monday. Alirocumab, developed along with French drugmaker Sanofi, belongs to a new...

  • *Merck gains after Pfizer deal. EDINBURGH, Nov 17- European shares turned solidly positive on Monday after ECB President Mario Draghi reasserted that he was ready to do more to fight deflation. Shrugging off worries that Japan's economy has unexpectedly slipped into recession, the market also drew confidence from earnings reports, merger and acquisition news...

  • Early Glance: Pharmaceuticals companies Monday, 17 Nov 2014 | 10:29 AM ET

    Baxter International Inc. fell$. 14 or. 2 percent, to $71.61. Bristol-Myers Squibb Co. rose$. 22 or. 4 percent, to $58.17. Hospira rose$. 12 or. 2 percent, to $58.40.

  • *Merck gains after Pfizer deal. EDINBURGH, Nov 17- European shares reclaimed early losses on Monday as concern over Japan's economy after it unexpectedly slipped into recession proved short-lived. Pharmaceutical firm Merck rose 3.8 percent, the index's top riser, after agreeing a deal with Pfizer for sharing rights to develop its experimental immunotherapy...

  • Stock futures decline as Japan slides into recession Monday, 17 Nov 2014 | 9:17 AM ET
    Traders on the floor of the New York Stock Exchange.

    U.S. stocks looked set to decline at the open on Monday, with global shares hit by the news that Japan had unexpectedly slipped into recession.

  • Early Movers: BHI, HAL, TSN, AGN, GM, MAR & more Monday, 17 Nov 2014 | 8:14 AM ET

    Some of the names on the move ahead of the open.

  • LONDON, Nov 17- An experimental lupus drug from AstraZeneca significantly improved the symptoms of lupus in a mid-stage clinical trial, boosting prospects for a medicine the company believes could become a major seller. AstraZeneca's sifalimumab works in a different way to Benlysta by targeting interferon, a protein involved in inflammation.

  • US stocks seen lower after Japan enters recession Monday, 17 Nov 2014 | 6:03 AM ET
    Traders on the floor of the New York Stock Exchange.

    U.S. stocks looked set to decline at the open on Monday, with global shares hit by the news that Japan had unexpectedly slipped into recession.

  • German Merck, Pfizer in immunotherapy deal Monday, 17 Nov 2014 | 5:47 AM ET

    Germany's Merck KGaA said Monday it struck an alliance over cancer immunotherapy drugs with Pfizer, triggering an upfront payment of $850 million by the U.S. drugmaker.

  • *Deal may reduce need for Pfizer to acquire AstraZeneca. FRANKFURT/ LONDON, Nov 17- Pfizer punctured investor expectations of a renewed bid for AstraZeneca on Monday by signing a major cancer drug deal with Germany's Merck KGaA, reducing the U.S. firm's need for Astra's products. Winning access to AstraZeneca's cancer pipeline has been viewed as a key goal for...

  • *GlaxoSmithKline again leads index for best drug access. The contradictory advances and the problems facing the industry are evident at GlaxoSmithKline, which retained its long-standing top spot in the index, while simultaneously featuring in a major bribery scandal in China. "Corruption is terrible, but it also takes attention away from the fact that these...

  • Final Glance: Pharmaceuticals companies Friday, 14 Nov 2014 | 6:03 PM ET

    Baxter International Inc. fell$. 33 or. 5 percent, to $71.75. Bristol-Myers Squibb Co. rose$. 15 or. 3 percent, to $57.95. Hospira rose$. 19 or. 3 percent, to $58.28.

  • Zoetis adopts shareholder rights plan Friday, 14 Nov 2014 | 5:47 PM ET

    Zoetis Inc. said Friday that it has adopted a one-year shareholder rights plan. Zoetis said the plan would enable existing shareholders a right to buy preferred stock if a person or group acquires at least 15 percent of the company's stock and tries to buy more. Shares of Zoetis fell 10 cent to close at $43.14 Friday.

  • Midday Glance: Pharmaceuticals companies Friday, 14 Nov 2014 | 1:17 PM ET

    Baxter International Inc. fell$. 31 or. 4 percent, to $71.77. Bristol-Myers Squibb Co. fell$. 03 or. 1 percent, to $57.77. Hospira fell$. 08 or. 1 percent, to $58.01.

  • Early Glance: Pharmaceuticals companies Friday, 14 Nov 2014 | 10:47 AM ET

    Baxter International Inc. fell$. 54 or. 7 percent, to $71.54. Bristol-Myers Squibb Co. fell$. 32 or. 6 percent, to $57.48. Johnson& Johnson fell$. 32 or. 3 percent, to $108.75.

  • LONDON, Nov 14- Pfizer appears unlikely to make a fresh bid for AstraZeneca in 12 days time, when an enforced cooling-off period ends, and the U.S. drugmaker is now weighing other less risky targets. People with direct knowledge of the situation said Pfizer has been reviewing different takeover scenarios with a U.S. investment bank ahead of Nov. 26, when it is allowed...